{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022598","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.631661+00:00","generated_at":"2026-06-22T05:54:14.993307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion Q3 net loss $22.9M, cash $133.8M; advances BMF-219 into KRAS solid tumors and T2D","bullets":["Net loss $22.9M in Q3 2022 ($12.6M in Q3 2021); cash & investments $133.8M vs $175.7M year-end 2021.","BMF-219 Phase I COVALENT-101 enrolling four liquid tumor cohorts; Cohort I at Dose Level 3, no DLTs; initial data H1 2023.","COVALENT-102 (Phase I/Ib) initiated for KRAS-mutated solid tumors (NSCLC, CRC, PDAC) under FDA clearance Oct 2022.","COVALENT-111 (Phase I/II) dosed first type 2 diabetes patient; healthy volunteer portion completed with no safety signals.","Expect IND submissions for BMF-500 (FLT3 inhibitor) and BMF-219 in T2D in H1 2023 and year-end 2022, respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022598","json":"https://secwatch.observer/filing/0000950170-22-022598.json","markdown":"https://secwatch.observer/filing/0000950170-22-022598.md","text":"https://secwatch.observer/filing/0000950170-22-022598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/0000950170-22-022598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/bmea-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:54:14.993307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2262d1f3d3b5130eb595c77849b601bd3aff896","claim":"Biomea Fusion, Inc. reported the quarter ended September 30, 2022 results: net income net loss attributable to common stockholders of $22.9 million.","evidence_excerpt":"On November 7, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/0000950170-22-022598-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"net loss attributable to common stockholders of $22.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}